ClinicalTrials.gg
Active, not recruitingNCT04493177Updated Oct 2, 2026

Educational Intervention in the First 18 Months of Life to Prevent/Manage Obesity of Children After Gestational Diabetes

An interventional study of Educational intervention and Conventional treatment Guia de Practica Clinica IMSS-029-08 in Gestational Diabetes and Overweight and Obesity, sponsored by Instituto Mexicano del Seguro Social. Active, not recruiting at 1 site in Mexico. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Instituto Mexicano del Seguro Social · Not applicable, Interventional, and Prevention

How we know

Updated Oct 2, 2026Results publication addedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
645
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

In order to evaluate the effect of an educational intervention on mothers with gestational diabetes and their offspring in the first 18 months of life, The intervention will be applied to mothers with gestational diabetes, and a group of mothers without diabetes, against a control group with the normal post-partum treatment. Effects on overweight and obesity will be evaluated in both mothers and offspring.

Read the detailed description

Effect of an education intervention for the prevention and management of overweight and obesity during the first 18 months of life of offspring and mother with gestational diabetes among insured of the Instituto Mexicano del Seguro Social.

ABSTRACT BACKGROUND: According to ENSANUT 2012, 9.7% of children \<5 years already are overweight or obese. Recently, an increase was reported in the frequency of overweight and obesity worldwide, beginning at earlier ages, especially in Mexico. The predisposition to chronic diseases in adults may be programmed in the womb ("fetal programming"). Also, women that suffer diabetes during pregnancy have a very high risk (6.4 times more) of developing diabetes in a middle range. The challenge for health personnel dedicated to the care of mother-child pairs is to achieve glycemic control from conception and to identify all the maternal-fetal secondary complications. To carry out compliance with adherence to medical management and/or healthy eating habits would allow us to reduce future overweight, obesity and the incidence of type 2 diabetes in mother-child pairs. Approaching the mother-child pair is a great opportunity to study the intervention, which would allow us not only have a new, useful awareness in the evaluation of educational strategies, but also to apply good practices of healthy habits for the prevention of obesity and to avoid progression to diabetes. For the aforementioned reasons, the objective is: to implement and evaluate the effect of an education intervention for the prevention and management of overweight and obesity during the first 18 months of life of child and in mothers with and without gestational diabetes in insured members of the Instituto Mexicano del Seguro Social.

MATERIAL AND METHODS. Pregnant women will be invited to participate, who receive their prenatal and/or birth care in the Unidad Médica de Alta Especialidad (UMAE) Gineco-Obstretric Hospital No. 4 (HGO #4) and UMAE HGO #3 of Centro Médico "La Raza" of IMSS. After acceptance and signing an informed consent to participate in the study, 645 mother-child pairs will be included, with and without gestational diabetes mellitus (GDM), which will be diagnosed according to the criteria of the American Diabetes Association; all mothers with be between 18 and 40 years old. There will be 3 groups of binomials: 1) with GDM, 2) without GDM who will received the education intervention, and 3) without GDM who will receive the conventional care IMSS offers to mothers and nursing infants, during the first 18 months post-partum.

At the time of canalization before delivery or cesarean, a blood sample (15 mL) will be taken from the mother for measurement of glucose, glucosylated hemoglobin (A1c) and lipid profile. After birth, blood (15 mL) will be extracted directly from the umbilical cord for measurement of the child's glucose and lipid profile. Once the pediatric doctor has carried out reanimation of the newborn, previously-standardized health staff will take anthropometric measurements. During the 18 months of follow-up from birth, the mother-child pair will be given appointments at 0, 1, 2, 3, 6, 9, 12, 15 and 18 months, in which health care personnel involved in the study (nutritionist, social worker, pediatrician and family doctor) will perform activities to promote health and prevent disease, directed towards the mother-child pair and planned within the education intervention strategy based on the First 1000 Days program, or the conventional care that mothers and nursing infants receive in IMSS, according to the study group. Weekly, the mothers will be sent, by digital media and social networks, educational material to promote healthy diet and physical activity; for the child material will include the promotion of exclusive breastfeeding until 6 months, at which time promotion will be of adequate complementary foods, in addition to early stimulation activities; educational material will be handed out: posters and brochures will serve to reinforce and remind of the information given during appointments. Also, characteristics of the diet consumed by mother and child will be recorded monthly, along with the physical activity performed by the mother.

The education intervention has as objective the acquiring of knowledge, motivation, creation of an awareness of disease, adoption of healthy diet and physical activity; its components will be individual sessions, group sessions, electronic messages, etc.

SAMPLE SIZE: The sample size necessary, with a 95% confidence interval and a power of 80%, is 645 mother-child pairs, among which 215 mother-child pairs will be included with mothers who presented gestational diabetes and will receive the education intervention, and 430 pairs without gestational diabetes (215 pairs with the education intervention and 215 with conventional care).

STATISTICAL ANALYSIS: Anthropometric and biochemical data will be described using mean and standard deviation for continuous variables, or percentages for nominal or ordinal variables. The difference between variables of offspring of mothers with and without GDM, as well as the difference between groups with and without education intervention, will be analyzed with Mann-Whitney U test, Student t test, or chi square, as appropriate. Multivariate analysis will be performed, using lineal regression in models of repeated measures, to evaluate the association between 1) child weight-for-age (in Z score), and 2) mother's BMI, and the education intervention or having presented GDM or no, according to the independent variable, or the exposure that is being analyzed (effect of GDM or effect of the intervention), controlling for possible confounding variables. Values of p\<0.05 will be considered statistically significant.

EXPECTED RESULTS: The education intervention was standardized in Boston, Mass, and will be implemented with the adaptation necessary for our population, in order to evaluate if it is better than the conventional treatment, for transference to the Family Medicine Units and second-level hospitals that have Gineco-obstetric services in the IMSS.

Included will be surveys on the opinion of doctors and participants to measure the acceptability of the intervention.

Expected results are: differences associated with the intervention in: a) body mass index and weight-for-age, respectively, in the mother-child pair; b) speed of growth and growth percentile score; as well as c) implementation of an education strategy that can be used as part of the care the mother-child pair receives.

DELIVERABLE PRODUCTS: Situational analysis of the mother-child pair, from the clinical point of view, laboratory studies, databases, plan for implementation of this strategy in IMSS. In addition, there will be databases that can be used for other analyses. DNA banks are contemplated, from serum and plasma, for scientific questions derived from this study.

SOCIAL IMPACT: This study will offer a model that can be implemented in all hospitals of IMSS that attend to births and/or cesareans. This will contribute to the timely prevention of obesity in insured families of IMSS, with an eye towards making it extend both at the national level for IMSS and for other health institutions. It is hoped that the education strategy will be a tool that allows a reduction in the frequency of overweight, obesity, and diabetes mellitus in our country.

DURATION OF THE STUDY: 5 years.

02

Conditions studied

  • Gestational Diabetes
  • Overweight and Obesity
03

In context

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

This study's planned enrollment of 645 is above the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

Instituto Mexicano del Seguro Social is the lead sponsor of 126 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-40 years old
  • insured by IMSS
  • with or without gestational diabetes

Exclusion criteria

Exclusion Criteria:

  • History of type 1 or 2 diabetes, MODY or secondary diabetes
  • CKD, hepatic or cardiac disease, pregnancy hypertension, corioamniotis orpremature membrane rupture, pulmonary maturity 24 hours before birth, severe complications
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
645 participants (estimated)

Study arms

  • Experimental
    Gestational diabetes intervention

    All mothers with gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.

    Behavioral: Educational intervention · Other: Conventional treatment Guia de Practica Clinica IMSS-029-08

  • Experimental
    No diabetes intervention

    Mothers without gestational diabetes will receive 18 months of educational intervention post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.

    Behavioral: Educational intervention · Other: Conventional treatment Guia de Practica Clinica IMSS-029-08

  • Active comparator
    No diabetes no intervention

    Mothers without gestational diabetes will receive the conventional care for 18 months post-partum. They and their offspring will be evaluated at months 1,2,3,6,9,12,15,and 18.

    Other: Conventional treatment Guia de Practica Clinica IMSS-029-08

Interventions

  • BehavioralEducational intervention

    Monthly 45-minute sessions will be held, including dietary, and physical activity modification, early stimulation, exclusive breastfeeding for 6 months and the proper introduction of foods, and other support for the mother. The sessions will be supported by personalized contact by WhatsApp and programmed telephone calls, in addition to conventional treatment.

  • OtherConventional treatment Guia de Practica Clinica IMSS-029-08

    Conventional treatment includes some early stimulation, monthly visits for height/weight measurement of the offspring.

06

What researchers measure

Primary outcomes

  1. Prevention of overweight/obesity in offspring, determined by z-score in the indicator for weight for age

    Offspring will be expected to have a difference of at least 0,3 standard deviations in z-score of the indicator for weight for age, as measured by weight on a standard weight scale over the course of the study, and compared with WHO growth charts.

    Time frame: 18 months

  2. Prevention of overweight/obesity mothers, determined by loss in body mass index (BMI)

    Mothers will be expected to have a loss of at least 1.8kg/m2 of body mass index (BMI, weight/height squared), as measured by weight, as measured by a standard weight scale, divided by height in meters squared over the course of the study.

    Time frame: 18 months

Secondary outcomes

  1. Changes in blood concentration of glucose: GDM

    Compare blood measurements of glucose of the mother over the 18 months of mothers with vs without gestational diabetes (GDM).

    Time frame: 18 months

  2. Changes in blood concentration of glucose: intervention

    Compare blood measurements of glucose of the mother over the 18 months of mothers with vs without educational intervention. .

    Time frame: 18 months

  3. Changes in blood concentration of glycosylated hemoglobin: GDM

    Compare blood measurements of glycosylated hemoglobin (HbA1c) of the mother over the 18 months of mothers with vs without gestational diabetes. .

    Time frame: 18 months

  4. Changes in blood concentration of glycosylated hemoglobin: intervention

    Compare blood measurements of glycosylated hemoglobin (HbA1c) of the mother over the 18 months of mothers with vs without educational intervention. .

    Time frame: 18 months

  5. Changes in blood concentration of lipids: GDM

    Compare blood measurements of lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides) of the mother over the 18 months of mothers with vs without gestational diabetes. .

    Time frame: 18 months

  6. Changes in blood concentration of lipids: intervention

    Compare blood measurements of lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides) of the mother over the 18 months of mothers with vs without educational intervention. .

    Time frame: 18 months

07

Study locations

1 site
  • Hospital Gineco-Obstetrico #4
    Mexico City, 06720, Mexico
08

References and documents

Publications

  • Ruiz-Martinez ML, Gomez-Diaz RA, Valdez-Gonzalez AL, Ramirez-Garcia LA, Acevedo-Rodriguez GE, Ramos-Cervantes MT, Diaz-Velazquez MF, Morales-Perez MA, Mondragon-Gonzalez R, Wacher NH. Association Between the Lifestyle Inflammation Score and Gestational Diabetes Mellitus and Postpartum Glucose Metabolism Alterations. Nutrients. 2025 Nov 27;17(23):3717. doi: 10.3390/nu17233717. PubMed 41374008 ↗
  • Soto Briseno AI, Gomez-Diaz RA, Saldana Espinoza RC, Lavielle P, Valdez Gonzalez AL, Wacher NH. Validation of the COVID-19 Fear Scale modified for application during the perinatal period. J Psychosom Obstet Gynaecol. 2022 Dec;43(4):447-452. doi: 10.1080/0167482X.2022.2050210. Epub 2022 Mar 16. PubMed 35294335 ↗

Individual participant data

Plan to share: No — Research will be shared upon written request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Sep 2027, 85 months after the start.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 85 months is above that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Aug 2025 → Sep 2027 and completion Aug 2025 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2020
First posted
Jul 30, 2020
StartActual
Aug 25, 2020
Primary completionEst.
Sep 30, 2027was Aug 2025
CompletionEst.
Sep 30, 2027was Aug 2025
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 25, 2025→Sep 30, 2027
Oct 2, 2026
Study completion
Aug 25, 2025→Sep 30, 2027
Oct 2, 2026
Publications
Results publication added: Ruiz-Martinez ML, Gomez-Diaz RA, Valdez-Gonzalez AL, Ramirez-Garcia LA, Acevedo-Rodriguez GE, Ramos-Cervantes MT, Diaz-Velazquez MF, Morales-Perez MA, Mondrago… PubMed 41374008 ↗. 1 publication citing this study linked from PubMed
Oct 2, 2026
Sponsor
Collaborators added: Fundación Gonzalo Río Arronte; collaborators removed: Fundacion Rio Arronte
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Publications Results publication added: Ruiz-Martinez ML, Gomez-Diaz RA, Valdez-Gonzalez AL, Ramirez-Garcia LA, Acevedo-Rodriguez GE, Ramos-Cervantes MT, Diaz-Velazquez MF, Morales-Perez MA, Mondrago… PubMed 41374008 ↗. 1 publication citing this study linked from PubMed
    Primary completion Aug 25, 2025→Sep 30, 2027
    Study completion Aug 25, 2025→Sep 30, 2027
    Sponsor Collaborators added: Fundación Gonzalo Río Arronte; collaborators removed: Fundacion Rio Arronte
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04493177
Collaborators
Massachusetts General Hospital, Fundación Gonzalo Río Arronte
Responsible party
Rita A. Gomez Diaz (Principal Investigator, Instituto Mexicano del Seguro Social) — Principal investigator
First posted
Jul 30, 2020
Start date
Aug 25, 2020
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Cesar R Gonzalez Bonilla, PhD
study chair · Secretary of Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion